Conference Day Two

Thursday, May 15, 2025

8:00 am Light Breakfast & Morning Networking

8:55 am Chair’s Opening Remarks

Targeting Unmet Areas for Transformative Therapies & Reversal of Disease Progression

9:00 am Refining Patient Stratification & Tailoring Pediatric Therapies to Transform IBD Care

  • Eileen Crowley Assistant Professor & Director, Pediatric IBD Centre, London Health Sciences Centre

Synopsis

  • Exploring age-specific markers for optimized pediatric IBD management
  • Advancing therapeutic approaches to address pediatric-specific challenges in IBD
  • Developing stratification protocols for personalized treatments in pediatric patients

9:30 am Panel Discussion: Enhancing Precision Medicine & Optimizing Stratification to Deliver Effective Fibrosis Therapies

  • Pratik Panchal Medical Director, Translational Medicine, Takeda Pharmaceutical
  • Mohamed Hassanein Associate Director - Precision Medicine & Early Clinical Development, Pfizer
  • Raj Kamath Executive Director, Merck & Co

Synopsis

  • Refining stratification approaches to identify high-risk patients for fibrosis
  • Tailoring therapies based on molecular and genetic fibrosis profiles
  • Can biopharma harness stratification tools to improve therapy outcomes and efficiency?

Supercharging IBD Treatment with Novel Therapeutic Pathways to Deliver Superior & Transformative Patient Care

11:00 am Harnessing PD-1 Agonists for Novel Therapeutic Approaches in Autoimmune Diseases

  • Bryan Linggi Senior Director- Translational Research, AnaptysBio

Synopsis

  • Exploring the novel mechanism of PD-1 agonists in T-cell modulation to treat autoimmune diseases
  • Leveraging biomarker data to refine patient selection and optimize therapeutic outcomes
  • Integrating translational research insights into clinical strategy for ulcerative colitis and other inflammatory conditions (RA)

11:30 am Development of a Novel Immune Checkpoint Enhancer as a Potential Therapeutic Medicine for Ulcerative Colitis

  • Judy Chou President and Chief Executive Officer, AltruBio

Synopsis

  • An in-depth exploration for the capacity of emerging approaches regarding non-immune cells to revolutionize our understanding of IBD
  • Exploring the capacity for precision medicine strategies target these unconventional players to open new avenues for IBD treatment innovation

12:00 pm Targeting CCR9: Advancing Precision Therapies for Inflammatory Bowel Disease

  • Sarah Grant Vice President & Head of Early Clinical Development Respiratory & Immunology, AstraZeneca

Synopsis

  • Leveraging CCR9 inhibition to improve therapeutic targeting and address IBD heterogeneitys
  • Exploring clinical outcomes and patient stratification strategies for CCR9-targeted therapies
  • Innovating treatment pathways to optimize safety and efficacy in precision medicine for IBD

12:30 pm Lunch Break & Networking

Deciphering Novel Targets & Preclinical Models to Accelerate Precision IBD Therapies & Enhance Clinical Success

1:30 pm Deciphering GPR35: A Novel Target for Epithelial-Driven Therapeutics in IBD

Synopsis

  • Unravelling the role of GPR35 in epithelial biology to address inflammatory bowel disease progression
  • Investigating the therapeutic potential of GPR35 antagonists in preclinical models and patient-derived systems
  • Exploring the use of biomarkers to stratify patients for targeted therapeutic interventions and enhanced clinical outcomes

2:00 pm Roundtable Discussion: Advancing Autoimmune Therapeutics: Precision Approaches to Inflammation

Synopsis

  • Exploring innovative therapies to address inflammation in autoimmune diseases
  • Leveraging melanocortin receptor agonists to combat inflammation in ulcerative colitis, bypassing the risks of broad immunosuppressants
  • Advancing precision medicine to improve outcomes for patients with chronic inflammatory conditions

3:00 pm Deciphering the Optimal Preclinical Models for Streamlined Stratification for More Efficacious Clinical Trials

Synopsis

  • How to identify preclinical models that accurately mimic patient heterogeneity and disease complexity
  • Evaluating the predictive power of preclinical models for improving molecular diagnostic evaluation of patients
  • How can one refine models to reduce clinical trial failure rates and improve translational outcomes

3:30 pm Chair’s Closing Remarks

3:40 pm End of 3rd Precision Medicine in Inflammatory Bowel Disease Summit